Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy
R Foglar, K Shibata, K Horie, A Hirasawa… - European Journal of …, 1995 - Elsevier
Several α1-adrenoceptor antagonists have recently been developed for the treatment of
benign prostatic hypertrophy because of their less frequent systemic side-effects compared
to conventional α1-adrenoceptor blockers. One potential explanation for their good
tolerability would be the selectivity for a certain subtype of α1-adrenoceptor. Utilizing COS-7
cells expressing the rat α1A, the hamster α1B and the human α1C-adrenoceptors, we
investigated affinities of alfuzosin, doxazisin, terazosin, indoramin and (+)-and (−)-5-[2-[[2-(o …
benign prostatic hypertrophy because of their less frequent systemic side-effects compared
to conventional α1-adrenoceptor blockers. One potential explanation for their good
tolerability would be the selectivity for a certain subtype of α1-adrenoceptor. Utilizing COS-7
cells expressing the rat α1A, the hamster α1B and the human α1C-adrenoceptors, we
investigated affinities of alfuzosin, doxazisin, terazosin, indoramin and (+)-and (−)-5-[2-[[2-(o …